Substance / Medication

Dofetilide

Overview

Active Ingredient
dofetilide
RxNorm CUI
49247
Labeler: Mayne Pharma Inc.Updated: 2026-02-10T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Dofetilide capsules are contraindicated in patients with congenital or acquired long QT syndromes. Dofetilide capsules should not be used in patients with a baseline QT interval or QTc >440 msec (500 msec in patients with ventricular conduction abnormalities). Dofetilide capsules are also contraindi

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Research Evidence

Published studies and systematic reviews

Sort:
Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil.
Vicente Jose, Johannesen Lars, Mason Jay W et al. · J Am Heart Assoc · 2015
PMID: 25870186RCTFull text (PMC)
The effect of dofetilide on ventricular defibrillation thresholds.
Simon Ron D B, Sturdivant J Lacy, Leman Robert B et al. · Pacing Clin Electrophysiol · 2009
PMID: 19140909RCT
Assessment of Sotalol and Dofetilide Dosing at a Large Academic Medical Center.
Ting Clara, Malloy Rhynn, Knowles Danielle · J Cardiovasc Pharmacol Ther · 2020
PMID: 32347108Observational
Applications of machine learning in decision analysis for dose management for dofetilide.
Levy Andrew E, Biswas Minakshi, Weber Rachel et al. · PLoS One · 2019
PMID: 31891645ObservationalFull text (PMC)
Safety of rapid switching from amiodarone to dofetilide in atrial fibrillation patients with an implantable cardioverter-defibrillator.
Sharma Sharan Prakash, Turagam Mohit, Atkins Donita et al. · Heart Rhythm · 2019
PMID: 30710741Observational
Dofetilide-Associated QT Prolongation: Total Body Weight Versus Adjusted or Ideal Body Weight for Dosing.
Wang Stephen Y, Welch Terrence D, Sangha Rajbir S et al. · J Cardiovasc Pharmacol · 2018
PMID: 29985283Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Dofetilide (substance)
SNOMED CT
116107002
UMLS CUI
C0114771
RxNorm CUI
49247
Labeler
Mayne Pharma Inc.

Clinical Data

This intervention maps to 9 entities in the Healos knowledge graph.

4
Conditions
2
Biomarkers
2
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.